Archives of Dermatological Research

, Volume 311, Issue 9, pp 721–730 | Cite as

Genetic assessment of ten Egyptian patients with Sjögren–Larsson syndrome: expanding the clinical spectrum and reporting a novel ALDH3A2 mutation

  • Khalda Amr
  • Hala T. El-Bassyouni
  • Samira Ismail
  • Eman Youness
  • Sherien M. El-Daly
  • Abeer Y. Ebrahim
  • Ghada El-KamahEmail author
Original Paper


Assessment of ten Egyptian patients with Sjögren–Larsson syndrome (SLS) detected; unusual clinical manifestations, a first report of brain atrophy in SLS, some patients exhibited neither retinal dots nor white matter changes previously reported as essential manifestations. We identified five mutations in ALDH3A2 gene including a novel one and suggest a founder effect. Sjögren–Larsson syndrome is a rare autosomal recessive inborn error of lipid metabolism caused by mutations in the ALDH3A2 gene that codes for fatty aldehyde dehydrogenase and result in a triad of ichthyosis, spasticity, and mental retardation. Clinical, radiological, biochemical, and neurophysiological evaluation in ten SLS patients descending from seven unrelated Egyptian pedigrees was followed by Sanger sequencing of ALDH3A2 performed by ABI 3500. All patients presented with SLS triad; ichthyosis, spasticity of four limbs and hyperreflexia with an intelligent quotient (IQ) ranging from (39 to 69). Other manifestations were dysmorphic features, seizures, and skeletal and ophthalmological affection. Mutational analysis of ALDH3A2 gene revealed three missense, one splice site, and one novel stop codon mutation; c.991G>T (p.E331X). Biochemical studies showed decrease of fatty aldehyde dehydrogenase activity. Our results reinforce the distinct clinical, radiological, and biochemical features of ALDH3A2-related SLS which are the clue for targeted molecular testing. Moreover, we present additional unreported clinical findings and a novel mutation thus expanding the phenotypic and mutational spectrum of this rare disorder.


ALDH3A2 gene ALDH activity Novel mutation Sjögren–Larsson syndrome 



  1. 1.
  2. 2.
    Rizzo WB, Heinz E, Simon M et al (2000) Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implications for Sjögren–Larsson syndrome. Biochem Biophys Acta 1535:1–9PubMedGoogle Scholar
  3. 3.
    Roy U, Das U, Pandit A, Debnath A (2016) Sjögren–Larsson syndrome: a rare disease of the skin and central nervous system. BMJ Case Rep 5:6. CrossRefGoogle Scholar
  4. 4.
    Nagappa M, Bindu PS, Chiplunkar S, Gupta N, Sinha S, Mathuranath PS, Bharath RD, Taly AB (2017) Child neurology: Sjögren–Larsson syndrome. Neurology 88(1):e1–e4PubMedCrossRefGoogle Scholar
  5. 5.
    Rizzo WB, Dammann AL, Craft DA (1988) Sjögren–Larsson syndrome Impaired fatty alcohol oxidation in cultured fibroblasts due to deficient fatty alcohol:nicotinamide adenine dinucleotide oxidoreductase activity. J Clin Invest 81(3):738–744PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Schwartz RA (2018) Dermatologic manifestations of Sjögren–Larsson Syndrome.
  7. 7.
    Vural S, Vural A, Akçimen F, Bağci IS, Tunca C, Gündoğdu Eken A, Ruzicka T, Bașak AN (2018) Clinical and molecular characterization and response to acitretin in three families with Sjögren–Larsson syndrome. Int J Dermatol 57:843–848PubMedCrossRefGoogle Scholar
  8. 8.
    Tavasoli A, Sayyahfar S, Behnam B (2016) A rare case of Sjögren–Larsson syndrome with recurrent pneumonia and asthma. Korean J Pediatr 59(6):276–279PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Gaboon NE, Jelani M, Almramhi MM, Mohamoud HS, Al-Aama JY (2015) Case of Sjögren–Larsson syndrome with a large deletion in the ALDH3A2 gene confirmed by single nucleotide polymorphism array analysis. J Dermatol 42(7):706–709PubMedCrossRefGoogle Scholar
  10. 10.
    Rizzo WB (2016) Genetics and prospective therapeutic targets for Sjögren–Larsson Syndrome. Expert Opin Orphan Drugs 4(4):395–406PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Chang C, Yoshida A (1997) Human fatty aldehyde dehydrogenase gene (ALDH10): organization and tissue-dependent expression. Genomics 40:80–85PubMedCrossRefGoogle Scholar
  12. 12.
    Rogers GR, Markova NG, De Laurenzi V, Rizzo WB, Compton JG (1997) Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH). Genomics 39:127–135PubMedCrossRefGoogle Scholar
  13. 13.
    Rizzo WB, Carney G, Lin Z (1999) The molecular basis of Sjögren–Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am J Hum Genet 65:1547–1560PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Rizzo WB, Carney G (2005) Sjögren–Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum Mutat 26:1–10PubMedCrossRefGoogle Scholar
  15. 15.
    Didona B, Codispoti A, Bertini E et al (2007) Novel and recurrent ALDH3A2 mutations in Italian patients with Sjögren–Larsson syndrome. J Hum Genet 52:865–870PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Auada MP, Puzzi MB, Cintra ML et al (2006) Sjögren–Larsson syndrome in Brazil is caused by a common c.1108-1G>C splice-site mutation in the ALDH3A2 gene. Br J Dermatol 154:770–773PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Davis K, Holden KR, S’Aulis D et al (2013) Novel mutation in Sjögren–Larsson syndrome is associated with divergent neurologic phenotypes. J Child Neurol 28:1259–1265PubMedCrossRefGoogle Scholar
  18. 18.
    Rizzo WB, Carney G, DeLaurenzi V (1997) A common deletion mutation in European patients with Sjögren–Larsson syndrome. Biochem Mol Med 62:178–181PubMedCrossRefGoogle Scholar
  19. 19.
    Sillen A, Anton-Lambrecht I, Braun-Quentin C et al (1998) Spectrum of mutations and sequence variants in the FALDH gene in patients with Sjögren–Larsson syndrome. Hum Mut 12:377–384PubMedCrossRefGoogle Scholar
  20. 20.
    Watkins MW, Beaujean AA (2014) Bifactor structure of the Wechsler Preschool and Primary Scale of Intelligence–Fourth Edition. Sch Psychol Q 29(1):52–63PubMedCrossRefGoogle Scholar
  21. 21.
    Rizzo WB, Craft DA (2000) Sjögren–Larsson syndrome: accumulation of free fatty alcohols in cultured fibroblasts and plasma. J Lipid Res 41(7):1077–1081PubMedGoogle Scholar
  22. 22.
    Willemsen MA, IJlst L, Steijlen PM, Rotteveel JJ, de Jong JG, van Domburg PH, Mayatepek E, Gabreëls FJ, Wanders RJ (2001) Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren–Larsson syndrome. Brain 124(Pt 7):1426–1437PubMedCrossRefGoogle Scholar
  23. 23.
    Human Genome Mutation Database (HGMD) (2018).
  24. 24.
    Lin Z, Carney G, Rizzo WB (2000) Genomic organization, expression, and alternate splicing of the mouse fatty aldehyde dehydrogenase gene. Mol Genet Metab 71:496–505PubMedCrossRefGoogle Scholar
  25. 25.
    Kraus C, Braun-Quentin C, Ballhausen WG, Pfeiffer RA (2000) RNA-based mutation screening in German families with Sjögren–Larsson syndrome. Eur J Hum Genet 8:299–306PubMedCrossRefGoogle Scholar
  26. 26.
    Carney G, Wei S, Rizzo WB (2004) Sjögren–Larsson syndrome: seven novel mutations in the fatty aldehyde dehydrogenase gene ALDH3A2. Hum Mutat 24(2):186PubMedCrossRefGoogle Scholar
  27. 27.
    Sarret C, Rigal M, Vaurs-Barriere C et al (2012) Sjögren–Larsson syndrome: novel mutations in the ALDH3A2 gene in a French cohort. J Neurol Sci 312:123–126PubMedCrossRefGoogle Scholar
  28. 28.
    Burgueño-Montañés C, García-Fernández M, Colunga-Cueva M, García-López A (2014) Sjögren–Larsson syndrome: optical coherence tomography and a novel mutation. Arch Soc Esp Oftalmol 89:504–507PubMedCrossRefGoogle Scholar
  29. 29.
    Amr K, Messaoud O, El Darouti M, Abdelhak S, El-Kamah G (2014) Mutational spectrum of Xeroderma pigmentosum group A in Egyptian patients. Gene 533(1):52–56 (Epub 2013 Oct 14) PubMedCrossRefGoogle Scholar
  30. 30.
    Rizzo WB, Craft DA (1991) Sjögren–Larsson syndrome: deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol NAD+ oxidoreductase in cultured fibroblasts. J Clin Invest 88:1643–1648PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Cho KH, Shim SH, Kim M (2018) Clinical, biochemical, and genetic aspects of Sjögren–Larsson syndrome. Clin Genet 93(4):721–730PubMedCrossRefGoogle Scholar
  32. 32.
    Engelstad H, Carney G, S’Aulis D, Rise J, Sanger WG, Rudd MK, Richard G, Carr CW, Abdul-Rahman OA, Rizzo WB (2011) Large contiguous gene deletions in Sjögren–Larsson syndrome. Mol Genet Metab 104(3):356–361PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Didona B, Codispoti A, Bertini E, Rizzo WB, Carney G, Zambruno G, Dionisi-Vici C, Paradisi M, Pedicelli C, Melino G, Terrinoni A (2007) Novel and recurrent ALDH3A2 mutations in Italian patients with Sjögren–Larsson syndrome. J Hum Genet 52(10):865–870PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Keller MA, Zander U, Je F et al (2014) A gatekeeper helix determines the substrate specificity of Sjögren–Larsson syndrome enzyme fatty aldehyde dehydrogenase. Nat Commun 5:4439PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Rizzo WB (2001) Sjögren–Larsson syndrome: fatty aldehyde dehydrogenase deficiency. The metabolic and molecular bases of inherited disease, vol 2, 8th edn. McGraw Hill, New York, pp 2239–2258Google Scholar
  36. 36.
    Kim JY, Kim SH, Park MJ, Kim SH, Cho WH, Choi J, Ki CS, You SJ (2018) Identification of homozygous likely pathogenic variant of ALDH3A2 in a Korean Boy with Sjögren–Larsson Syndrome. Ann Lab Med. 38:80–82PubMedCrossRefGoogle Scholar
  37. 37.
    Zribi H, Souissi A, Azzouz H, Drissi C, Ben Hamouda M, Tabib N, Mokni M, Ben Osman A (2014) Sjögren–Larsson syndrome: a rare neurocutaneous disease. Rev Neurol (Paris) 170(4):297–298CrossRefGoogle Scholar
  38. 38.
    Hargrove JL, Greenspan P, Hartle DK (2004) Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes. Exp Biol Med (Maywood) 229(3):215–226CrossRefGoogle Scholar
  39. 39.
    Rizzo WB (2014) Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function. Biochim Biophys Acta 1841:377–389PubMedCrossRefGoogle Scholar
  40. 40.
    El-Bassyouni HT, Said OA, Abdel Maksoud S (2005) Clinical and biochemical changes in Egyptian patients with Sjögren–Larsson syndrome. Egypt J Med Hum Genet 6:135–144Google Scholar
  41. 41.
    Kariminejad A, Barzgar M, Bozorgmehr B, Keshavarz E, Kariminejad MH, S’Aulis D, Rizzo WB (2017) Novel mutations and a severe neurological phenotype in Sjögren–Larsson syndrome patients from Iran. Eur J Med Genet 61(3):139–144PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Molecular Genetics DepartmentNational Research CentreCairoEgypt
  2. 2.Clinical Genetics DepartmentNational Research CentreCairoEgypt
  3. 3.Medical Biochemistry DepartmentNational Research CentreCairoEgypt
  4. 4.Medicinal and Aromatic Plant ResearchesNational Research CentreCairoEgypt

Personalised recommendations